- Home
- SXTC vs SLS Comparison
SXTC vs SLS Comparison
Compare SXTC & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SXTC | SLS |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.7M | 208.0M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | SXTC | SLS |
|---|---|---|
| Price | $2.52 | $3.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 697.1K | ★ 6.3M |
| Earning Date | 08-19-2019 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,537,987.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.34 | $0.95 |
| 52 Week High | $1,175.99 | $5.18 |
Technical Indicators
Market Signals| Indicator | SXTC | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 59.84 | 48.45 |
| Support Level | $2.34 | $3.49 |
| Resistance Level | $6.40 | $3.90 |
| Average True Range (ATR) | 0.42 | 0.35 |
| MACD | 0.24 | -0.11 |
| Stochastic Oscillator | 39.18 | 16.88 |
Price Performance
Historical ComparisonAbout SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.